{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:54:36Z","timestamp":1747158876512,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.diagmicrobio.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T18:43:08Z","timestamp":1488480188000},"page":"192-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-5345","authenticated-orcid":false,"given":"Derek N.","family":"Bremmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan-Miquel","family":"Balada-Llasat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karri A.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"Performance standards for antimicrobial susceptibility testing (M100-S21)","author":"Clinical and Laboratory Standard Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2017.02.019_bb0005"},{"year":"2013","series-title":"Performance standards for antimicrobial susceptibility testing (M100-S22)","author":"Clinical and Laboratory Standard Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2017.02.019_bb0010"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus Pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2011.04005.x","article-title":"Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal","volume":"72","author":"Garot","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/47.4.421","article-title":"The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients","volume":"47","author":"Joynt","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0040","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus Pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0050","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0055","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0060","article-title":"Elevated staphylococcus ceftriaxone MICs are an Etest artifact","author":"Limbago","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0065","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/AAC.39.8.1764","article-title":"Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model","volume":"39","author":"Palmer","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s11096-014-9999-5","article-title":"Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections","volume":"36","author":"Patel","year":"2014","journal-title":"Int J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0075","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.02.019_bb0090","series-title":"49th Interscience conference on antimicrobial agents and chemotherapy","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate susceptibility breakpoints for labeled ceftriaxone dosing regimens","author":"Van Wart","year":"2009"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:20:40Z","timestamp":1535998840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317300755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0732889317300755"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.02.019","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}